Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.
Figure 4

Figure 4. Percentage of PDL-1 expression among splenic CD33+CD14−HLA-DR+ cells.. From: Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study.

Ref. = reference group made of patients with serous cystadenoma (open dots) and of patients with splenic non-neoplastic lesions; PaCa = Ductal adenocarcinoma; NETs = Neuroendocrine tumors. Kruskal-Wallis test: p = 0.046.

Daniela Basso, et al. PLoS One. 2013;8(1):e54824.
2.
Figure 2

Figure 2. Ratio between splenic and circulating CD33+CD14−HLA-DR+ immature myeloid cells.. From: Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study.

Ref. = reference group made of patients with chronic pancreatitis and of patients with splenic non-neoplastic lesions; BPNs = Borderline pancreatic neoplasms; PDAC = Ductal adenocarcinoma; NETs = Neuroendocrine tumors. Boxes represent interquartile ranges with medians; bars represents minimum and maximum values.

Daniela Basso, et al. PLoS One. 2013;8(1):e54824.
3.
Figure 6

Figure 6. CTLA4 negative dendritic cells suppress T cell proliferation.. From: Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study.

Panel A: CD33+CD14HLA-DR+PDL1+ and CD33+CD14HLA-DR+PDL1 cells were FACS sorted and cocultured with allogenic T cells and proliferation was evaluated by (3H)-thymidine incorporation. Assay was performed in triplicate; data are mean ± SE of 4 independent experiments. Panel B: CTLA4+ and CTLA4 dendritic cells were FACS sorted and cocultured with allogenic T cells and proliferation was evaluated by (3H)-thymidine incorporation. Assay was performed in triplicate; data are mean ± SE of 3–4 independent experiments.

Daniela Basso, et al. PLoS One. 2013;8(1):e54824.
4.
Figure 5

Figure 5. S100A8/A9 induces PDL1 and inhibits CTLA4.. From: Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study.

Healthy PBMC were analysed by flow cytometry after they have been cultured for 2 days in the absence (Control) or presence of 10 nM S100A8/A9 heterocomplex. Immature myeloid cells were gated on the basis of CD33 expression. Panel A: percentage variations of CD14+HLA-DR MDSCs; panel B: percentage variations of CTLA4 among CD14+HLA-DR MDSCs; panel C: percentage variations of CD14HLA-DR+ dendritic cells; panel D: percentage variations of PDL1 among CD14HLA-DR+ dendritic cells.

Daniela Basso, et al. PLoS One. 2013;8(1):e54824.
5.
Figure 1

Figure 1. Individual levels of CD8+ T cells in blood of the studied patients.. From: Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study.

Ref. = reference group made of patients with chronic pancreatitis (open dots) and of patients with splenic non-neoplastic lesions; SCA = Serous cystadenoma; BPNs = Borderline pancreatic neoplasms; PDAC = Ductal adenocarcinoma; NETs = Neuroendocrine tumors; Other = Non-pancreatic tumors. Each dot represents one case, and each open square represents five cases. * = p<0.0001 with respect to Ref. and p<0.001 with respect to BPNs.

Daniela Basso, et al. PLoS One. 2013;8(1):e54824.
6.
Figure 3

Figure 3. Immature myeloid cells in peripheral blood.. From: Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study.

Panel A (upper left): a typical example of gating of low, intermediate (Int.) and high complexity sets among CD33+ cells in flow cytometry. Panel B (upper right): low, intermediate and high complexity CD33+ cells were analysed on the basis of CD14 and HLA-DR expression. A typical example is shown in this panel. Panel C (lower left): Blood low complexity CD33+CD14HLA-DR+ cells. Panel D (lower right): blood low complexity CD33+CD14HLA-DR cells. Ref. = reference group made of patients with chronic pancreatitis (open dots) and of patients with splenic non-neoplastic lesions; BPNs = Borderline pancreatic neoplasms; PDAC = Ductal adenocarcinoma; NETs = Neuroendocrine tumors. * = p<0.004 (adjusted p-value for significance) with respect to Reference.

Daniela Basso, et al. PLoS One. 2013;8(1):e54824.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk